EnviroTech :: Manufacturing Excellence
Lonza Signs Manufacturing Deal with U.S. Biopharma Firm
12:30 AM MDT | May 19, 2009 | Deepti Ramesh
Lonza says it has entered into a manufacturing services agreement with biopharmaceutical company Morphotek (Exton, PA), to support the development and manufacturing of a subset of antibodies in Morphotek’s therapeutic antibody pipeline. According to the agreement, Lonza will reserve capacity for commercial manufacturing of Morphotek’s lead compound farletuzumab, which recently entered Phase III clinical trials for ovarian cancer. Morphotek, a subsidiary of pharmaceutical company Eisai Corporation (Woodcliff Lake, NJ), specializes in the development of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee